NCCN Guidelines for Patients® | Multiple Myeloma - page 53

53
NCCN Guidelines for Patients™: Multiple Myeloma
Version 1.2012
Par t 8
Par t 7
Par t 6
Par t 5
Par t 4
Par t 3
Par t 2
Par t 1
Definitions:
!
See pages 26 – 29
for more information
on transplants.
5.4 Active multiple myeloma
Part 5.4.7 describes treatment options after an allogeneic stem cell transplant.
If there was a treatment response or the disease is stable, you can choose
between maintenance treatment and observation. A list of maintenance
treatments can be found in Part 5.4.5.
If the cancer returns or progresses, you have a choice between salvage
therapy and donor lymphocyte infusion. A list of salvage therapies can be found
in Part 5.4.3. A donor lymphocyte infusion is when you are given white blood
cells from the same donor of stem cells for the allogeneic transplant.
5.4.7 Treatment after allogeneic stem cell transplant
Treatment
Test results
Progressive
disease or
relapse
Response or
stable disease
Observation
Maintenance treatment on clinical trial, or
Salvage therapy on or off clinical trial, or
Donor lymphocyte infusion
Allogeneic stem cell
transplant:
Treatment
with stem cells from a donor
Anemia:
A health condition
in which the number of red
blood cells is low
Autologous stem cell
transplant:
Treatment
with your own stem cells
M-protein:
An abnormal
antibody made by myeloma
cells that doesn’t fight germs
Maintenance treatment:
Medicine given to continue
good primary treatment
results
‘Mini’ allogeneic
transplant:
Low-dose
chemotherapy is given
before transplant
Salvage therapy:
Treatment given after
other treatments failed
1...,43,44,45,46,47,48,49,50,51,52 54,55,56,57,58,59,60,61,62,63,...84
Powered by FlippingBook